Guinea Resilience System

cdc.gov - April 3, 2015

In late October 2014, Ebola virus disease (Ebola) was diagnosed in a humanitarian aid worker who recently returned from West Africa to New York City (NYC). . . .

. . . In NYC, the public health response to one Ebola case was resource intensive for a local health department, with participation of more than 500 DOHMH staff members and expenditures of more than $4,300,000 in DOHMH funds. These figures include not only the direct costs of the local public health response (e.g., contact tracing, environmental issues, and health care worker monitoring) but also the indirect costs of increasing citywide preparedness after identifying the one case (e.g., enhancing hospital preparedness, active monitoring of returning travelers, and community outreach).

(READ COMPLETE ARTICLE)

Baz Ratner/Reuters

thedailybeast.com - by Sheldon Yett - April 3, 2015

The worst of the Ebola epidemic may be over in Liberia, but the damage it inflicted on an already weak health care system could have catastrophic consequences.

Here in Liberia, the goal of zero Ebola cases is tantalizingly close. Only one new case has been recorded since 19 February, and 13 of the country’s 15 counties have not reported any new cases for over 42 days. But Ebola’s impact will be felt long after the last case has been treated.      

As the battle against Ebola continues, the threat of outbreaks of measles, whooping cough and other vaccine-preventable diseases remains high. Given the mobility of Liberia’s population, the danger is that these diseases could spread with the same devastating rapidity that Ebola did.

Malnutrition rates have also increased, and a large proportion of the population is still not using health facilities for fear of contracting Ebola.

(READ COMPLETE ARTICLE)

who.int - April 1, 2015

SUMMARY

REUTERS by Sharon Bagley                                                                      April 1, 2015

Early-stage trials of an experimental Ebola vaccine, two in the United States and four in Africa and Europe, have found that it appears to be safe and triggered robust production of Ebola-fighting antibodies, scientists reported on Wednesday.

Since trials cannot ethically expose volunteers to Ebola, the production of antibodies is a proxy for whether vaccines could prevent or even treat the disease.

The trials all tested a vaccine called VSV-ZEBOV, which was developed at the Public Health Agency of Canada and licensed to NewLink Genetics Corp and then to Merck & Co Inc. It consists of a cattle virus called rVSV that has been engineered to carry Ebola genes, which produce proteins meant to trigger production of anti-Ebola antibodies.

According to separate teams of scientists, that is what happened, two papers in the New England Journal of Medicine reported.

Read complete story.
http://www.reuters.com/article/2015/04/01/us-health-ebola-vaccine-idUSKBN0MS5DN20150401

Read NEW ENGLAND JOURNAL OF MEDICINE  papers